海正药业(600267.SH)：全资子公司通过药品GMP符合性检查

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration for its subsidiary, Haizheng Pharmaceutical Nantong Co., Ltd, indicating successful compliance with GMP standards for its newly established production line of Minocycline Hydrochloride [1] Group 1: GMP Compliance and Production - The GMP compliance inspection for Minocycline Hydrochloride is the first for this drug prior to its market launch, and it is the first successful GMP compliance check for the newly built production line [1] - The total fixed asset investment in the relevant workshop has reached approximately 99.16 million yuan, with about 86.3 million yuan already completed (unaudited) [1] - The successful GMP compliance indicates that the production line and drug meet GMP requirements, which will help the company diversify its product offerings and maintain stable production capacity to meet market demand [1] Group 2: Market Context and Competitors - Minocycline Hydrochloride is used to treat infections caused by various sensitive pathogens, with the original manufacturer being Wyeth Pharmaceuticals in the United States [1] - Major domestic manufacturers of Minocycline Hydrochloride include Haizheng Nantong Co., Ltd and Zhejiang Changhai Pharmaceutical Co., Ltd [1] - The approval notice for the market launch of Minocycline Hydrochloride was obtained in August 2025, indicating a future market entry [1]